Universe Pharmaceuticals INC

NasdaqCM:UPC Stock Report

Market Cap: US$2.9m

Universe Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Universe Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth23.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Universe Pharmaceuticals INC (NASDAQ:UPC) Not Doing Enough For Some Investors As Its Shares Slump 44%

Nov 14
Universe Pharmaceuticals INC (NASDAQ:UPC) Not Doing Enough For Some Investors As Its Shares Slump 44%

Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price Plunge

Sep 27
Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price Plunge

Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With Revenues

Jul 22
Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With Revenues

Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 31%

May 22
Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Universe Pharmaceuticals INC's (NASDAQ:UPC) Shares Bounce 27% But Its Business Still Trails The Industry

Apr 07
Universe Pharmaceuticals INC's (NASDAQ:UPC) Shares Bounce 27% But Its Business Still Trails The Industry

Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 27%

Feb 07
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 27%

There's No Escaping Universe Pharmaceuticals INC's (NASDAQ:UPC) Muted Revenues Despite A 54% Share Price Rise

Dec 18
There's No Escaping Universe Pharmaceuticals INC's (NASDAQ:UPC) Muted Revenues Despite A 54% Share Price Rise

Universe pharmaceuticals receives Nasdaq notification regarding minimum bid price deficiency

Jul 19

Improved Earnings Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Shares Find Their Feet

Feb 21
Improved Earnings Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Shares Find Their Feet

We Think That There Are Some Issues For Universe Pharmaceuticals (NASDAQ:UPC) Beyond Its Promising Earnings

Aug 10
We Think That There Are Some Issues For Universe Pharmaceuticals (NASDAQ:UPC) Beyond Its Promising Earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Universe Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:UPC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202427-19-6-6N/A
12/31/202330-12-3-2N/A
9/30/202332-611N/A
6/30/202333-9-1-1N/A
3/31/202334-11-3-3N/A
12/31/202237-10-2-2N/A
9/30/202240-9-1-1N/A
6/30/202244-1-61N/A
3/31/2022486-113N/A
12/31/2021489-130N/A
9/30/20214811-16-2N/A
6/30/20214310-8-2N/A
3/31/20213910-1-1N/A
12/31/202035922N/A
9/30/202031866N/A
6/30/20203181010N/A
3/31/20203191414N/A
12/31/20193281314N/A
9/30/20193381313N/A
9/30/201829844N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if UPC's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if UPC's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if UPC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if UPC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if UPC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if UPC's Return on Equity is forecast to be high in 3 years time


Discover growth companies